Desmoplastic stroma and cholangiocarcinoma: Clinical implications and therapeutic targeting

Hepatology

Volumn 59, Issue 6, 2014, Pages 2397-2402

  Sirica, Alphonse E ^a   Gores, Gregory J ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; SCLEROPROTEIN; VISMODEGIB;

BILE DUCT CARCINOMA; CANCER ASSOCIATED FIBROBLAST; CANCER GROWTH; CANCER PREVENTION; CANCER PROGNOSIS; CANCER SIZE; DESMOPLASTIC STROMA; FIBROBLAST; HUMAN; LIVER FIBROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STROMA; SURVIVAL RATE; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE;

ACTINS; ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FIBROBLASTS; HUMANS; MOLECULAR TARGETED THERAPY; PROGNOSIS;

EID: 84901621666     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26762     Document Type: Review

References (38)

1. Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2012;9:44-54.
2. Kajiyama K, Maeda T, Takenaka K, Sugimachi K, Tsuneyoshi M. The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma: a special reference of "scirrhous-type" and "nonscirrhous-type" growth. Am J Surg Pathol 1999;23:892-902.
3. Chuaysri C, Thuwajit P, Paupairoj A, Chau-In S, Suthiphongchai T, Thuwajit C. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol Rep 2009;21:957-969.
4. Okabe H, Beppu T, Hayashi H, Horino K, Masuda T, Komori H, et al. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009;16:2555-2564.
5. Campbell DJW, Dumur CI, Lamour NF, DeWitt JL, Sirica AE. Novel organotypic culture model of cholangiocarcinoma progression. Hepatol Res 2012;42:1119-1130.
6. Kadaba R, Birke H, Wang J, Hooper S, Andl CD, Di Maggio F, et al. Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. J Pathol 2013;230:107-117.
7. Aishima S, Nishihara Y, Iguchi T, Taguchi K, Taketomi A, Maehara Y, et al. Lymphatic spread is related to VEGF-C expression and D2-40-positive myofibroblasts in intrahepatic cholangiocarcinoma. Mod Pathol 2008;21:256-264.
8. Nishihara Y, Aishima S, Hayashi A, Iguchi T, Fujita N, Taketomi A, et al. CD10+ fibroblasts are more involved in the progression of hilar/extrahepatic cholangiocarcinoma than of peripheral intrahepatic cholangiocarcinoma. Histopathology 2009;55:423-431.
9. Utispan K, Thuwajit P, Abiko Y, Charngkaew K, Paupairoj A, Chau-in S, et al. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer 2010;9:13.
10. Dumur CI, Campbell DJW, DeWitt JL, Oyesanya RA, Sirica AE. Differential gene expression profiling of cultured neu-transformed versus spontaneously-transformed rat cholangiocytes and of corresponding cholangiocarcinomas. Exp Mol Pathol 2010;89:227-235.
11. Utispan K, Sonongbua J, Thuwajit P, Chau-in S, Pairojkul C, Wongkham S, et al. Periostin activates integrin α5β1 through a PI3K/AKT-dependent pathway in invasion of cholangiocarcinoma. Int J Oncol 2012;41:1110-1118.
12. Fujimoto K, Kawaguchi T, Nakashima O, Ono J, Ohta S, Kawaguchi A, et al. Periostin, a matrix protein, has potential as a novel serodiagnostic marker for cholangiocarcinoma. Oncol Rep 2011;25:1211-1216.
13. Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei XF, et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 2010;101:1913-1919.
14. Subimerb C, Pinlaor S, Khuntikeo N, Leelayuwat C, Morris A, McGrath MS, et al. Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma. Mol Med Rep 2010;3:597-605.
15. Subimerb C, Pinlaor S, Lulitanond V, Khuntikeo N, Okada S, McGrath MS, et al. Circulating CD14+CD16+ monocyte levels predict tissue invasive character of cholangiocarcinoma. Clin Exp Immunol 2010;161:471-479.
16. Chang J, Hisamatsu T, Shimamura K, Yoneno K, Adachi M, Naruse H, et al. Activated hepatic stellate cells mediate the differentiation of macrophages. Hepatol Res 2013;43:658-669.
17. Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res 2006;66:6622-6627.
18. DeClerck YA. Desmoplasia: a response or a niche? Cancer Discov 2012;2:772-774.
19. Ling H, Roux E, Hempel D, Tao J, Smith M, Lonning S, et al. Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. PLOS One 2013;8:e54499.
20. Pinlaor S, Prakobwong S, Hiraku Y, Pinlaor P, Laothong U, Yongvanit P. Reduction of periductual fibrosis in liver fluke-infected hamsters after long-term curcumin treatment. Eur J Pharmacol 2010;638:134-141.
21. Prakobwong S, Khoontawad J, Yongvanit P, Pairojkul C, Hiraku Y, Sithithaworn P, et al. Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis. Int J Cancer 2011;129:88-100.
22. Philips GM, Chan IS, Swiderska M, Schroder VT, Guy C, Karaca GF, et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLOS One 2011;6:e23943.
23. Pratap A, Singh S, Mundra V, Yang N, Panakanti R, Eason JD, et al. Attenuation of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling. J Drug Target 2012;20:770-782.
24. Kim Y, Fiel MI, Albanis E, Chou HI, Zhang W, Khitrov G, et al. Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate. Liver Int 2012;32:1008-1017.
25. Mertens JC, Fingas CD, Christensen JD, Smoot RL, Bronk SF, Werneburg NW, et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res 2013;73:897-907.
26. Omenetti A, Diehl AM. Hedgehog signaling in cholangiocytes. Curr Opin Gastroenterol 2011;27: 268-275.
27. Fingas CD, Bronk SF, Werneburg NW, Mott JL, Guicciardi ME, Cazanave SC, et al. Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling in cholangiocarcinoma cells. Hepatology 2011;54:2076-2088.
28. Fingas CD, Mertens JC, Razumilava N, Bronk SF, Sirica AE, Gores GJ. Targeting PDGFR-β in cholangiocarcinoma. Liver Int 2012;32:400-409.
29. Cadamuro M, Nardo G, Indraccolo S, Dall'olmo L, Sambado L, Moserle L, et al. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology 2013;58:1042-1053.
30. Wiedmann MW, Mössner J. Molecular targeted therapy of biliary tract cancer - results of the first clinical studies. Curr Drug Targets 2010;11:834-850.
31. Clapéron A, Mergey M, Aoudjehane L, Huong T, Ho-Bouldoires TH, Wendum D, et al. Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. Hepatology 2013;58:2001-2011.
32. Khatib ME, Kalnytska A, Palagani V, Kossatz U, Manns MP, Malek NP, et al. Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma. Hepatology 2013;57:1035-1045.
33. Sirica AE, Campbell DJ, DeWitt JL. Organotypic cell culture modeling of desmoplastic cholangiocarcinoma progression. Hepatology 2012;56:616A (abstract).
34. Walter K, Omura N, Hong S-M, Griffith M, Vincent A, Borges M, et al. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clin Cancer Res 2010;16:1781-1789.
35. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-1461.
36. Chan IS, Guy CD, Chen Y, Lu J, Swiderska-Syn M, Michelotti GA, et al. Paracrine hedgehog signaling drives metabolic changes in hepatocellular carcinoma. Cancer Res 2012;72:6344-6350.
37. Garber K. Stromal depletion goes on trial in pancreatic cancer. JNCI 2010;102:448-450.
38. Alberici L, Roth L, Sugahara KN, Agemy L, Kotamraju VR, Teesalu T, et al. De Novo design of a tumor-penetrating peptide. Cancer Res 2013;73:804-812.